| Literature DB >> 27983552 |
Marwan N Sabbagh1, Barbara Schäuble2, Keshav Anand1, Danielle Richards3, Shigeo Murayama4,5, Hiroyasu Akatsu6,7, Masaki Takao5,8, Christopher C Rowe9, Colin L Masters10, Henryk Barthel11, Hermann-Josef Gertz12, Oliver Peters13, Natalie Rasgon14, Aleksandar Jovalekic15, Osama Sabri11, Walter J Schulz-Schaeffer16, John Seibyl17.
Abstract
Of 57 individuals diagnosed with Alzheimer's disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology.Entities:
Keywords: Alzheimer’s disease; florbetaben PET; histopathology
Mesh：
Substances：
Year: 2017 PMID： 27983552 DOI： 10.3233/JAD-160821
Source DB: PubMed Journal: J Alzheimers Dis ISSN： 1387-2877 Impact factor: 4.472